[Click eStock] "ABL Bio, Potential Innovative Drug for Dementia Treatment 'BBB Shuttle'"

[Asia Economy Reporter Ji Yeon-jin] Kyobo Securities estimated on the 7th that ABL Bio's 'BBB shuttle' technology, developed by the company, is likely to be recognized as global pharmaceutical companies' investment trends in degenerative brain disease treatments are being confirmed.

ABL Bio is a bispecific antibody specialized biotechnology company developing CNS disease treatments such as Parkinson's disease and immuno-oncology drugs. The BBB shuttle developed by the company, used in Parkinson's disease treatment development (IGF1R), is a method to deliver drugs to nerve cells, which can dramatically increase the currently low drug delivery rate to nerve cells.

With the U.S. FDA approval of Aduhelm, an Alzheimer's treatment jointly developed by U.S. pharmaceutical company Biogen and Japan's Eisai, global pharmaceutical companies are actively investing in dementia treatments.

Researcher Kim Jeong-hyun of Kyobo Securities said, "ABL111 and ABL503, co-developed with I-Mab, entered U.S. clinical trials earlier this year, and sequential dosing is underway," adding, "Especially, the CLDN18.2-targeting bispecific antibody ABL111 has great potential as a First-In-Class innovative anticancer drug."